Synthetic analogues of somatostatin with longer half-lives are utilised in clinical practice, including first-generation (octreotide and lanreotide) and second-generation (pasireotide) agents, for a variety of indications (e.g., acromegaly, neuroendocrine tumours, bleeding oesophageal varices) given the effects of somatostatin to inhibit secretion of other hormones and influence splanchnic blood flow (as discussed in Section 5.1) [82]. Here, SST is linked to varicose disease.